Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Arbutus Biopharma Corp

ABUS
Current price
3.21 USD +0.11 USD (+3.55%)
Last closed 3.07 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 579 361 152 USD
Yield for 12 month +22.52 %
1Y
3Y
5Y
10Y
15Y
ABUS
21.11.2021 - 28.11.2021

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. Address: 701 Veterans Circle, Warminster, PA, United States, 18974

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

4.4 USD

P/E ratio

Dividend Yield

Current Year

+18 141 000 USD

Last Year

+39 019 000 USD

Current Quarter

+1 532 000 USD

Last Quarter

+2 145 000 USD

Current Year

+16 737 000 USD

Last Year

+37 592 000 USD

Current Quarter

+1 177 000 USD

Last Quarter

+1 786 000 USD

Key Figures ABUS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -78 652 000 USD
Operating Margin TTM -1252.15 %
PE Ratio
Return On Assets TTM -29.31 %
PEG Ratio
Return On Equity TTM -57.54 %
Wall Street Target Price 4.4 USD
Revenue TTM 12 986 000 USD
Book Value 0.64 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -77.1 %
Dividend Yield
Gross Profit TTM -45 389 000 USD
Earnings per share -0.44 USD
Diluted Eps TTM -0.44 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ABUS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ABUS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:5
Payout Ratio
Last Split Date 04.11.2010
Dividend Date

Stock Valuation ABUS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 22.0536
Price Sales TTM 28.9019
Enterprise Value EBITDA -5.636
Price Book MRQ 4.9455

Financials ABUS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ABUS

For 52 weeks

1.69 USD 3.29 USD
50 Day MA 2.77 USD
Shares Short Prior Month 5 170 836
200 Day MA 2.33 USD
Short Ratio 2.92
Shares Short 5 805 594
Short Percent 3.91 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

425.34 USD Microsoft Corporation +5.34 (+1.27%)
Detailed analytics

ETF funds


S

SX7EEX

14.76 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) +0.11 (+0.7%)
Detailed analytics

Metals


Gold

2415.8 USD Gold +1.74 (+0.07%)
Detailed analytics